Oncotarget

Research Papers:

Daurinol blocks breast and lung cancer metastasis and development by inhibition of focal adhesion kinase (FAK)

Jong Kyu Woo, Hyun Jin Jung, Ji-Youn Park, Ju-Hee Kang, Byung Il Lee, Dong Yun Shin, Chu Won Nho, Soo-Young Cho, Je Kyung Seong and Seung Hyun Oh _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:57058-57071. https://doi.org/10.18632/oncotarget.18983

Metrics: PDF 804 views  |   HTML 1656 views  |   ?  


Abstract

Jong Kyu Woo1,2, Hyun Jin Jung2, Ji-Youn Park1, Ju-Hee Kang1, Byung Il Lee3, DongYun Shin1, Chu Won Nho4, Soo-Young Cho3, Je Kyung Seong2,* and Seung Hyun Oh1,*

1Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Republic of Korea

2Korea Mouse Phenotyping Center, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea

3National Cancer Center, Goyang-si, Republic of Korea

4Korea Institute of Science and Technology (KIST), Gangneung Institute, Gangneung-si, Republic of Korea

*These are authors contributed equally to this work

Correspondence to:

Seung Hyun Oh, email: eyeball@hanmail.net, eyeball@gachon.ac.kr

Keywords: daurinol, breast cancer, lung cancer, FAK, metastasis

Received: January 16, 2017     Accepted: June 18, 2017     Published: July 04, 2017

ABSTRACT

FAK overexpression has been reported in diverse primary and metastatic tumor tissues, supporting its pro-tumorigenic and pro-metastatic roles. Therefore, we have developed a neo-treatment strategy using daurinol to effectively treat cancer metastasis. Daurinol blocked cancer cell migration and invasion in vitro and exhibited anti-metastatic activity in an experimental metastasis model of breast and lung cancer. Daurinol selectively inhibited phosphorylation of FAK at Tyr925, Tyr576/577, and Tyr397 sites in a dose- and time-dependent manner. Daurinol effectively suppressed migration and invasion of MDA-MB-231 and A549 cancer cells. These data were associated with inhibition of expression and secretion of invasion factors, including matrix metalloproteinase (MMP) 2, MMP9, and urokinase plasminogen activator (uPA). Consistent with these in vitro results, daurinol (10 mg/kg; Oral gavage) effectively inhibited breast and lung cancer metastasis in a mouse model. In addition, daurinol showed strong suppressive activity of cell survival as revealed by colony formation assays. Analysis of cellular phenotypes revealed that inhibition of FAK phosphorylation in cancer cells limited colony formation, cell migration, and invasion, thereby reducing the cell proliferation rate. Furthermore, daurinol significantly reduced tumor development in 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK)/benzo(a)pyrene (BaP)-treated A/J mice. Our results suggest that daurinol suppresses lung metastasis through inhibition of migration and survival via blockade of FAK activity.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18983